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We present a new next-generation sequencing-based method to identify somatic mutations of lung cancer. It is a 
comprehensive mutation profiling protocol to detect somatic mutations in 30 genes found frequently in lung adeno-
carcinoma. The total length of the target regions is 107 kb, and a capture assay was designed to cover 99% of it. This method 
exhibited about 97% mean coverage at 30× sequencing depth and 42% average specificity when sequencing of more than 
3.25 Gb was carried out for the normal sample. We discovered 513 variations from targeted exome sequencing of lung 
cancer cells, which is 3.9-fold higher than in the normal sample. The variations in cancer cells included previously reported 
somatic mutations in the COSMIC database, such as variations in TP53, KRAS, and STK11 of sample H-23 and in EGFR of 
sample H-1650, especially with more than 1,000× coverage. Among the somatic mutations, up to 91% of single nucleotide 
polymorphisms from the two cancer samples were validated by DNA microarray-based genotyping. Our results 
demonstrated the feasibility of high-throughput mutation profiling with lung adenocarcinoma samples, and the profiling 
method can be used as a robust and effective protocol for somatic variant screening.
Keywords: high-throughput nucleotide sequencing, lung neoplasms, next-generation sequencing, selector technology, 
somatic mutation screening, target enrichment
Introduction
Non-small-cell lung cancer is an increasingly common and 
lethal disease, accounting for 25% of all cancer deaths. 
Sequencing of the lung cancer genome is of particular 
interest for identifying driver mutations and their pathways 
involved in cancer growth and development [1]. Somatic 
mutational profiles are crucial for cancer diagnosis and 
classification, which lead to tailoring the best therapeutic 
strategy to individual patients [2]. 
Previous studies using the Sanger sequencing method 
have identified several key mutations associated with lung 
cancer. Massive PCR amplification and Sanger sequencing of 
623 candidate cancer genes in 188 lung adenocarcinomas 
discovered 26 mutational target genes [3]. Although the 
study provided highly valuable results, it is very time- 
consuming and costly－so much so that a single laboratory 
can hardly perform this kind of large-scale sequencing 
projects. 
A mass spectrometric-based mutation detection techno-
logy, named OncoMap, has been effective in identifying 
somatic mutations in cancer genomes [4]. Currently, it can 
detect more than 1,000 mutations in 112 commonly mu-
tated genes that were previously identified as oncogenes and 
tumor suppressors [5]. Although OncoMap is a high- 
throughput method for mutational profiling with both fresh 
frozen and paraffin-embedded tissue samples, the mutation 
detection is limited to previously identified mutations, and it 
cannot discover novel mutations. 
Recent advancements of next-generation sequencing 
technology have made breakthroughs in identifying un-
known somatic mutations [6]. Combined with sequencing 
technology, targeted enrichment techniques have been 
developed to reduce sequencing cost and time [7]. Several 
recent studies have reported targeted resequencing of cancer 
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samples using next-generation sequencing technologies [8, 
9]. 
Here, we present a fast and cost-effective method to 
identify somatic mutations in lung cancer. We surveyed the 
literature and chose 30 mutational target genes that were 
associated strongly with lung adenocarcinoma development. 
Target gene capture was performed using selector probes, 
which involved circularization and amplification of specific 
restriction fragments covering the target genes using rolling 
circle amplification [10]. The captured target DNAs were 
analyzed by next-generation sequencing to find somatic 
variations. This method could be useful to detect previously 
known recurrent mutations as well as novel variations.
Methods
Preparation of genomic DNA from cancer cell lines 
We ordered normal genomic DNA sample from the Coriell 
Institute Cell Repository (CCR ID NA17022; Camden, NJ, 
USA), which originated from a normal Caucasian male of 
European descent. For cancer genomic DNAs, H-1650 and 
H-23 cancer cells were cultured and harvested for DNA 
preparation. Genomic DNA (gDNA) was extracted with the 
QIAamp DNA blood kit according to the manufacturer's 
instructions (Qiagen, Hilden, Germany). The DNA quality 
and quantity were assessed with the use of a Nanodrop 
spectrophotometer (Thermo Fisher Scientific, Wilmington, 
DE, USA).
Design and oligonucleotides
The list of the entire exons for the 30 genes was obtained 
from a consensus coding sequence database, CCDS (build 
36.3), showing a total number of 701 exons covering 102 kb, 
according to hg18 (March, 2006 assembly). 
Targeted restriction fragments were selected using 
Disperse software [11]. Templates for circularization of each 
chosen targeted fragment (selector probes) were designed 
using ProbeMaker software [12]. Each selector probe 
consisted of two sequences of 20－25 nucleotides comple-
mentary to the ends of its targeted restriction fragment. 
The 3'-biotin-labeled oligonucleotides (Integrated DNA 
Technologies, Coralville, IA, USA) were prepared by incu-
bating the oligonucleotides with 1× Tdt buffer (NEB), 1× 
CoCl2 (NEB), 0.1 mM dUTP-biotin (Roche Diagnostics, 
Mannheim, Germany), and 0.2 units/μL terminal trans-
ferase (NEB) in a final volume of 50 μL. The reaction was 
incubated at 37°C for 1 h and followed by enzyme 
inactivation at 75°C for 20 min.
Target enrichment
Eight different restriction reactions were used to digest 
genomic DNAs from each sample, including SfcI and 
Hpy188I in NEB buffer 4; DdeI and AluI in NEB buffer 2; MseI 
and Bsu36I in NEB buffer 3; MslI and BfaI in NEB buffer 4; 
HpyCH4III and Bsp1286 in NEB buffer 4; SfcI and NlaIII in 
NEB buffer 4; MseI and HpyCH4III in NEB buffer 4; and 
HpyCH4V and EcoO109I in NEB buffer 4 (New England 
Biolabs, Ipswich, MA, USA). The restriction reactions con-
tained 1 unit each of two restriction enzymes and their 
corresponding compatible NEB buffer in 1× concentration 
and 0.85 μg/μL bovine serum albumin (BSA) in a total 
volume of 10 μL. The reactions were incubated at 37°C for 
60 min, followed by enzyme inactivation at 80°C for 20 min. 
A total of 80 μL of pooled digested sample was mixed 
with 10 pM biotinylated selector probes, 1 M NaCl, 10 mM 
Tris-HCl (pH 7.5), 5 mM EDTA, and 0.1% Tween-20 in a 
total volume of 160 μL. The mixture was incubated and 
hybridized at 95°C for 10 min, 75°C for 30 min, 68°C for 30 
min, 55°C for 30 min, and 46°C for 10 h. The hybridized 
solution was mixed with 10 μL M-280 streptavidin-coated 
magnetic beads (3.35 × 107 beads/mL; Invitrogen, Carlsbad, 
CA, USA) in 1 M NaCl, 10 mM Tris-HCl (pH 7.5), 1 mM 
EDTA, and 0.1% Tween-20 in a final volume of 200 μL and 
incubated at room temperature for 10 min. After incubation, 
the beads were collected using a ring magnet and washed in 
1 M NaCl, 10 mM Tris-HCl (pH 7.5), 5 mM EDTA, and 0.1% 
Tween-20 in a total volume of 200 μL at 46°C for 30 min 
with rotation.
Multiple displacement amplification 
Genomic fragments were circularized by incubating the 
beads with 1× Ampligase reaction buffer, 0.25 U/μL 
Ampligase (Epicentre, Madison, WI, USA), and 0.1 μg/μL 
BSA in a total volume of 50 μL at 55°C for 10 min. The 
circularized molecules were separated from the beads by 
incubation with 5 μL sample buffer at 95°C for 10 min and 
collected with a ring magnet rack. The supernatant was 
incubated with 5 μL reaction buffer and 0.2 μL enzyme mix 
(Templiphi; GE Life Sciences, Piscataway, NJ, USA) at 30°C 
for 4 h, followed by inactivation at 65°C for 10 min.
Real-time quantitative PCR analysis
The enriched samples were analyzed with real-time 
quantitative PCR (qPCR) and DNA quantification to eva-
luate enrichment bias and specificity. PCR primers were 
placed randomly in the targeted regions and quality 
controlled using standard genomic DNA. The qPCR results 
were used to estimate how much target DNA was present in 
the amplification products, and then, the specificity 
(proportion target material) was estimated by measuring the 
amount of DNA in the reactions.
The enriched and pre-enriched control DNAs were diluted 
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(final dilution 1:3,600) in a PCR mix containing 1× PCR 
buffer, 2 mM MgCl2, 1 unit Platinum Taq, 0.2 mM dNTP 
(10297-018; Invitrogen), 1× SYBR Green I, 10% DMSO, and 
0.16 μM of either on-target primer or off-target primer to a 
total volume of 30 μL. The genomic reference DNA was 10 
ng of template in the same PCR mixture as described above. 
The qPCR was performed using an LC480 Real-Time PCR 
system (Roche), and the conditions were as follows: 95°C for 
5 min followed by 40 cycles of (95°C 15 s, 56°C 30 s), with 
end-point measurement of the fluorescence after each 
completed cycle.
Library preparation and massive parallel sequencing 
Libraries were prepared according to the manufacturer's 
instructions (Illumina, San Diego, CA, USA). Briefly, 5 μg of 
gDNA in 200 μL nuclease-free water was fragmented by a 
Bioruptor (Diagenode, Liege, Belgium) at high power for 30 
min (30 s ON and 30 s OFF). Overhangs of fragmented 
gDNA were converted to blunt ends using T4 DNA ligase 
and Klenow enzyme. Subsequently, an ‘A’ base was added to 
the ends of double-stranded DNA using Klenow exo- (3' to 5' 
exo minus). The paired-end adaptor (Illumina) with a single 
‘T’ base overhang at the 3' end was ligated to the products 
above. The PE adaptor-ligated products were separated on a 
2% agarose gel and excised from the gel from approximately 
400 bp to 500 bp. The sequencing libraries were bar-coded to 
allow sequencing of 6 samples in one lane of a flow cell. 
Size-selected DNA fragments were enriched by PCR with PE 
primers 1.1 and 2.1 (Illumina). The concentration of the 
libraries was measured on both a Nanodrop (Thermo Fisher 
Scientific) and Qubit IT (Invitrogen). Finally, the libraries 
were validated by a Bioanalyzer (Agilent Technologies, Santa 
Clara, CA, USA). The gDNA library was sequenced using the 
Illumina genome analyzer GAIIx according to the manu-
facturer’s instructions.
Short read alignment and variation calling 
A total of 76-bp paired-end or single-end sequence reads 
with ~200-bp insert size were aligned to the human 
reference genome (NCBI build 37, hg19) with BWA algo-
rithm1 ver. 0.5.8c and default parameters [13]. Two mis-
matches were permitted in a 45-bp seed sequence. Putative 
single nucleotide polymorphisms (SNPs) and small INDELs 
were called by the pileup vcf function of Samtools (ver.0.1.9) 
[14]. The options used in filtering variations were a 
minimum of 6 for mapping depth and quality threshold of 50 
for single nucleotide variations (SNVs) and 20 for small 
INDELs. Predicted SNVs were compared with NCBI dbSNP 
version 131 (http:// www.ncbi.nlm.nih.gov/projects/SNP/) 
to remove known SNP information. Non-synonymous SNV 
information was extracted by comparing UCSC (http:// 
genome.ucsc.edu/) reference gene information with the 
somatic mutation list in the COSMIC cancer information 
database (http://www. sanger.ac.uk/genetics/CGP/cosmic/). 
PolyPhen (polymorphism phenotyping) was utilized to pre-
dict possible changes in protein structure and function 
resulting from a non- synonymous amino acid change.
Genome-wide SNP analysis 
SNP genotyping was performed using the Axiom geno-
typing solution, including an Axiom Genome-Wide ASI 1 
Array Plate and reagent kit, according to the manufacturer’s 
protocol (Affymetrix, Santa Clara, CA, USA). Briefly, total 
genomic DNA (200 ng) was treated with 20 μL of dena-
turation buffer and 40 μL neutralization buffer, followed by 
amplification for 23 h using 320 μL of Axiom amplification 
mix. Amplified DNA was randomly fragmented into 25 to 
125 base pair (bp) sizes with 57 μL of Axiom fragmentation 
mix at 37°C for 30 min, followed by DNA precipitation for 
DNA clean-up and recovery. DNA pellets were dried and 
resuspended with 80 μL of hybridization master mix; 3 μL 
of suspended sample was kept for sample qualification. A 
hybridization-ready sample was denatured using a PCR 
machine at 95ºC for 20 min and 48ºC for 3 min. Denatured 
DNA was transferred to a hybridization tray and loaded onto 
a GeneTitan MC with an Axiom ASI array plate (Affymetrix). 
Hybridization continued on the GeneTitan for 24 h, followed 
by loading of ligation, staining, and stabilization reagent 
trays into the instrument. After chip scanning, the cel in-
tensity file was normalized, and genotype calling was done 
using Genotyping Console 4.1 with Axiom GT1 algorithms 
according to the manufacturer’s manual. The cut-off values 
for data quality control were DISHQC ≥ 0.82 for hybri-
dization and QC call rate ≥ 97%.
Results
Capture design
The 30 genes known to be mutated in lung cancer were 
chosen for targeted resequencing (Table 1). The 701 coding 
regions in 30 genes covered 102 kb according to the 
consensus coding sequence (CCDS) database. Capture 
sequences to achieve redundant coverage over the coding 
regions were chosen based on length (100－1,000 bp) and 
GC content (20－65%) and to avoid repetitive genomic 
elements in the ends. After analysis of in silico-digested 
restriction fragments of the target regions, the best 
combinations of restriction enzymes were selected to 
provide over 99% coverage of targeted bases.
Target enrichment analysis
A normal sample (NA17022) and two lung adenocar-
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Gene name No. of exons Total exon length (bp) H-1650 (%)
a H-23 (%)a NA17022 (%)a Reference
ALK 29 5,153 98 98 99 [15]
APC 15 8,674 98 99 100 [16]
ATM 62 9,781 93 94 99 [3, 17]
CDKN2A 4 1,028 0 64 75 [18]
EGFR 30 4,178 99 98 97 [19]
EML4 24 3,122 99 100 98 [15]
EPHA3 17 3,122 99 99 99 [20]
EPHA5 19 3,252 94 94 98 [3]
ERBB2 27 4,038 94 93 93 [21]
ERBB4 28 4,207 97 98 99 [3]
FGFR4 16 2,643 92 88 91 [22]
GNAS 14 2,057 99 99 97 [3]
INHBA 3 1,221 100 100 98 [3]
KDR 30 4,371 96 96 96 [3]
KRAS 5 737 100 100 100 [23]
LRP1B 90 14,591 97 98 98 [24]
LTK 21 2,731 81 81 84 [3]
NF1 62 12,585 96 99 99 [3]
NRAS 4 610 100 100 100 [25]
NTRK1 19 2,703 99 98 95 [3]
NTRK3 19 2,791 99 98 99 [3]
PAK3 15 1,736 90 95 100 [3]
PDGFRA 22 3,490 99 99 99 [3]
PIK3CA 20 3,403 98 98 100 [26]
PTPRD 32 6,020 99 98 99 [27, 28]
RB1 28 3,000 71 82 99 [3]
SLC38A3 15 1,664 99 99 99 [3]
STK11 9 1,392 87 94 95 [29]
TP53 10 1,282 87 99 99 [30]
ZMYND10 12 1,443 98 97 95 [3]
aPercentage of the sequenced bases in each target genes at 30×.
Table 1. 30× coverage of individual target genes after deep sequencing
Sample Estimatedspecificity (%)a
Standard
deviationb
Coefficient
of variation (%)c
H-1650 20.97 2.7 13
H-23 28.91  6.53 23
NA17022 28.53 5.4 19
qPCR, real-time quantitative PCR.
aProportion of the target DNA amount after enrichment, esti-
mated by measuring the relative amounts of target and 
non-target DNA in qPCR reactions; bStandard deviation of the 
estimated specificity (n = 3); cPercentage of the standard 
variation when divided by the estimated specificity.
Table 2. Target capture specificity analyzed by qPCRcinoma cell lines (H-1650 and H-23) were examined in this 
study. It is reported in the COSMIC database that the H-1650 
cell line has a deletion mutation in the EGFR gene, while the 
H-23 cell line has mutations in the KRAS, STK11, and TP53 
genes. 
After target gene enrichment, the enriched DNAs were 
analyzed using qPCR with primers targeting the regions of 
interest, along with qPCR primers targeting irrelevant, non- 
amplified loci outside the target regions. The correlation 
between the replicates was high (average r2 = 0.97), and the 
majority of primer pairs clustered within a range of 3 Cts 
(threshold cycle in qPCR). Therefore, the enrichment was 
highly reproducible, and the enrichment bias was minimal. 
The enriched DNAs showed an average Ct of 17 with the 
target primers, while primer pairs targeting loci outside of 
the target regions had average Cts of 33. This indicated that 
the enrichment was target-specific. The average specificity in 
the normal samples was 28% when calculated from the Ct 
and amount of enriched product (Table 2).
Sequencing analysis of enriched DNAs
To analyze the enriched samples, we sequenced the DNAs 
using a GAIIx next-generation sequencing instrument (Illu-
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Sample Sequencing type Total reads
Nucleotides
(Gb)
Mapped
reads
Mapped
nucleotides 
(Gb)
Mapping
rate (%)a
Mapped
reads to ROI
ROI mapped/ 
Total mapped 
(%)b
H-1650 76bp PE 57,068,802 4.34 51,497,175 3.91 90.24 14,543,373 28.24
H-23 76bp PE 79,351,316 6.03 67,717,575 5.15 85.34 17,961,341 26.52
NA17022 76bp SE 42,774,401 3.25 31,237,523 2.37 73.03 12,990,041 41.58
aPercentage of the total number of reads aligned to the human reference genome; bPercentage of the uniquely aligned reads to 
the region of interest (ROI).
Table 3. Mapping statistics of next-generation sequencing experiments
Fig. 1. Target coverage in cancer and normal samples. The 
cumulative coverage of targeted bases (i.e., the fraction of all 
sequenced bases in the target regions that share more than a 
particular read depth) were plotted after sequencing 4.34 Gb of 
H-1650 (black), 6.03 Gb of H-23 (blue), and 3.25 Gb of NA17022
(red). The sequencing yield in the three samples resulted in 30×
coverage of 92% (H-1650), 95% (H-23), and 97% (NA17022) of
all target regions.
mina) and evaluated important metrics to consider actual 
coverage, specificity, and reproducibility across the targeted 
loci. 
On average, 4.3 gigabases (Gb) was produced per sample, 
and they were mapped to the reference genome (NCBI build 
37, hg19) at a 73－90% mapping rate (Table 3). 
The 26－41% of the uniquely mapped reads were found in 
the region of interest, demonstrating moderate specificity of 
this approach. The normal sample showed the lowest 
mapping rate (73.03%) but the highest specificity (41.58%), 
indicating that cancer genomes are less efficient for exome 
sequencing due to genomic changes.
In addition, about 97% of the targeted bases were covered 
at more than 30× (Fig. 1). This high depth coverage could 
allow us to examine low-purity cancer samples, which are 
not normally analyzed by Sanger sequencing or genotyping 
tools. The actual coverage of the normal sample differed, 
depending on the gene. The coverage of most target genes 
was more than 95% at 30×, but two genes, CDKN2A and 
LTK, showed low coverage of 75% and 84%, respectively 
(Table 1). 
Using the final mapped reads, we constructed a genomic 
profile database for detecting SNVs (Supplementary Table 1) 
and short insertions and deletions (INDELs) (Supplemen-
tary Table 2). In each sample, we identified 81－179 SNVs 
and 50－90 small INDELs in target gene regions (Table 4). 
Cancer samples (H-1650 and H-23) showed about twice as 
many SNVs than the normal sample (NA17022).
By subtracting SNVs found in the SNP databases, we 
identified cancer-specific somatic mutation candidates, and 
identical somatic mutations of the cancer cell lines in the 
COSMIC database were found. All previously known so-
matic mutations in the TP53, KRAS, and STK11 genes of 
sample H-23 and in the EGFR gene of sample H-1650 were 
identified in this study (Table 4).
The validity of the data was also examined with a 
genome-wide SNP microarray, which has 37 SNPs in the 
target region (Axiom Array; Affymetrix). The genotyping 
data showed 80－91% concordance without any bias (Table 
5). The disconcordant variations were not biased to any 
sample, coverage, or genotype.
Discussion
Our targeted resequencing method for somatic mutation 
profiling in lung cancer from 30 cancer-related genes pro-
duced unbiased target DNAs repeatedly. Analysis of the 
enriched DNAs by next-generation sequencing identified 
previously known mutations in the samples. Further ana-
lysis of more samples by targeted resequencing will reveal 
many novel variant candidates.
Target enrichment was performed using Selector tech-
nology (Halo Genomics, Uppsala, Sweden), which showed 
improved coverage and compatibility with next-generation 
sequencing library construction by employing rolling-circle 
amplification [10]. This method exhibited about 97% mean 
coverage at 30× depth, average 42% specificity, and high 
reproducibility (r2 = 0.98) of target enrichment in the 
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Sample
SNVs Short insertions and deletions (INDELS)
No. of SNVs No. of nsSNVs SNVs No. of INDELs INDEL in EGFR gene
H-1650 163 101 Wild type 90 Deletion in exon 21 (GGAATTAAGAGAAGC)
H-23 179 110 G12C (KRAS)
M246I (TP53)
W332Stop (STK11)
81 Wild type
NA17022  81  34 Wild type 50 Wild type
SNV, single nucleotide variation; nsSNV, non-synonymous single nucleotide variation.
Table 4. Somatic variation candidates from the target gene regions
Sample SNVsa Coveredb Homo samec Homo differenced Hetero same
e Hetero
differencef Concordance
H-1650 37 36 (97) 28 3 0 4 28 (80)
H-23 37 35 (94) 28 3 4 0 32 (91)
Values are presented as number (%).
SNV, single nucleotide variation. 
aTotal number of genetic loci in the target region that DNA microarray can genotype; bTotal number of sequenced bases overlapping 
with DNA microarray genotyping data; cHomozygous genotypes concordant with the microarray genotyping results; dHomozygous 
genotypes different from the microarray genotyping results; eHeterozygous genotypes concordant with the microarray genotyping results; 
fHeterozygous genotypes different from the microarray genotyping results.
Table 5. Comparison of SNV calls with DNA microarray genotyping results
normal sample (Tables 1－3), indicating that this is appli-
cable to targeted resequencing of clinical samples. Although 
the enrichment specificity was moderate, this was overcome 
by increasing sequencing depth. As the total DNA bases of 
the target regions was 107 kb, 97% coverage at 30× depth 
was achieved by 3.25 Gb of sequencing, which does not 
create any cost issues by using next-generation sequencing 
technologies.
Exome resequencing has proven to be robust and effective 
for somatic variant detection in coding regions [31, 32]. 
Comparisons of sequencing data from normal and cancer 
tissues from individual patients have unveiled individual 
somatic mutation profiles. However, the cancer cell lines 
that we used had no normal cell pairs. To solve this problem, 
we tried to remove previously known normal variations as 
much as possible. Predicted SNVs from the sequencing data 
were further filtered using common variation information 
from the most updated dbSNP database. As a result, we 
found many somatic mutations, which included previously 
reported mutations in the COSMIC database, such as 
variations in TP53, KRAS, and STK11 of sample H-23 and in 
EGFR of sample H-1650 (Table 4). Especially, the number of 
reads that covered the four variations was more than 1,000. 
This provides many advantages when compared to whole- 
genome sequencing or whole-exome sequencing. Sequen-
cing of cancer samples has raised several issues, such as 
sample purity and cancer heterogeneity. These shortcomings 
can only be overcome by in-depth sequencing of target 
regions. Therefore, our protocol is also useful for cost- 
effective somatic mutation screening of admixed clinical 
cancer samples.
Compared to whole-genome sequencing, targeted se-
quencing has an issue with uneven coverage of targeted 
genes. In Table 3, cancer samples showed fewer sequencing 
reads at target regions. This low target capture efficiency in 
cancer samples could be explained by genetic variations in 
cancer genomes that inhibit the hybridization between 
cancer DNA fragments and the designed capture oligo-
nucleotides. This may be overcome by trial-and-error scree-
ning in selecting more efficient oligonucleotides. 
There are two kinds of target capture technologies: hybri-
dization and PCR. Hybridization-based target capture has 
been widely used and is able to cover more target regions but 
is time-consuming and hard to handle with many samples. In 
contrast, the PCR-based method is faster and allows us to 
handle more samples. Our protocol is a multiple displace-
ment amplification-based method that is as efficient as the 
PCR-based method. For example, hybridization-based target 
capture methods, such as the Agilent SureSelect target 
enrichment kit and NimbleGen SeqCap EZ kit, normally 
handle 1－8 samples at the same time, while our protocol 
with a liquid handler could process 96 samples in parallel. 
This costs 12 times less money. Therefore, our target enrich-
ment is scalable and easy to handle with multiple samples. 
56 www.genominfo.org
EH Kim, et al. Targeted Resequencing in Lung Adenocarcinoma
This can result in remarkable reduction of total cost when 
combined with multiplexed next-generation sequencing. 
Therefore, our target resequencing protocol provides a scal-
able sample-handling tool for a genetic variation study of 
lung adenocarcinoma.
Supplementary materials
Supplementary data including two tables can be found 
with this article online at http://www.genominfo.org/src/ 
sm/gni-12-50-s001.pdf.
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